H. Lundbeck A/S- (NASDAQ:HLUYY) has been given an average broker rating score of 3.00 (Hold) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a hold rating.

Zacks has also assigned H. Lundbeck A/S- an industry rank of 82 out of 265 based on the ratings given to related companies.

A number of analysts recently issued reports on HLUYY shares. Zacks Investment Research cut H. Lundbeck A/S- from a “buy” rating to a “hold” rating in a research report on Monday, July 17th. Deutsche Bank AG cut H. Lundbeck A/S- from a “hold” rating to a “sell” rating in a research report on Friday, July 28th.

COPYRIGHT VIOLATION WARNING: This news story was first posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/09/08/brokerages-anticipate-h-lundbeck-as-hluyy-to-post-0-52-eps.html.

H. Lundbeck A/S- (HLUYY) traded up 3.26% during midday trading on Friday, hitting $66.67. The company had a trading volume of 781 shares. The company has a market cap of $13.15 billion and a price-to-earnings ratio of 42.01. H. Lundbeck A/S- has a 12 month low of $31.00 and a 12 month high of $66.67. The firm has a 50-day moving average price of $61.02 and a 200-day moving average price of $52.67.

About H. Lundbeck A/S-

H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia.

Get a free copy of the Zacks research report on H. Lundbeck A/S- (HLUYY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for H. Lundbeck A/S- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H. Lundbeck A/S- and related companies with MarketBeat.com's FREE daily email newsletter.